JAMES FLEMING: Open Payments
NPI 1841525631 · LATTA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$683 in 42 payments from 16 companies in 2025. Trend: 2023 $484 · 2024 $455 · 2025 $683
Food & beverage: $683
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $186 |
| ABBVIE INC. | 10 | $138 |
| Corcept Therapeutics | 3 | $70 |
| Lilly USA, LLC | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Novo Nordisk Inc | 2 | $33 |
| Alkermes, Inc. | 1 | $27 |
| Exact Sciences Corporation | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Insulet Corporation | 1 | $18 |
Products named: TRELEGY ELLIPTA, Korlym, VRAYLAR, UBRELVY, MOUNJARO, CAPLYTA, QULIPTA, VIVITROL.
Industry payments across SC — which companies pay providers there.
